STENTYS Acquires New Self-Apposing Stent Delivery Capability

STENTYS, manufacturer of the world-first self-apposing coronary stent, is to enhance its offering with the acquisition of the assetts of a company called Cappella Peel Away, Inc., including its novel stent delivery platform technology.


U.S. and France-based Self-Apposing® Stent maker, STENTYS is a frequent visitor to our pages with a procession of good news stories about the performance of its unique design. As reported recently, a presentation at EuroPCR 2014 saw its APPOSITION IV study yielding excellent results compared with conventional, balloon-expandable comparators.

Now STENTYS has announced the signing of an agreement to acquire Cappella Peel Away Inc. and its assets relating to a novel stent delivery system. The catheter-based technology will enable the implantation of the Self-Apposing stent in the same manner as a conventional balloon-expandable stent. To release the stent in the vessel at the desired location, the cardiologist inflates a small balloon that splits open the stent-containing sheath. This technology has been used as part of Cappella’s Sideguard® coronary bifurcation stent, which is CE Marked in Europe and has been clinically validated by an extensive number of Sideguard stent implants.

Cappella Peel Away Inc. assets consist of a license agreement on patents related to the novel peel away sheath technology for a stent delivery system, technical specifications and drawings, clinical and regulatory documentation and equipment from Cappella Inc. The latter will retain the rights to the peel-away sheath technology for its Sideguard coronary bifurcation stent and for other potential applications including peripheral vascular indications.

STENTYS will incorporate the technology into its next-generation delivery system for the company’s line of bare metal and drug-eluting stents and expects to start commercializing these in 2015.

Company comments

Gonzague Issenmann, co-founder and Chief Executive Officer of STENTYS said: “This is STENTYS’ first strategic acquisition, and it results from our active research efforts, including constant monitoring of the landscape for complementary tools to add to our portfolio. We are very excited about the potential for the Cappella Peel Away catheters to offer cardiologists an even friendlier user experience for implantation of our stents and allow more heart attack patients to benefit from STENTYS’ Self-Apposing technology.”

Source: STENTYS, Business Wire

Share your thoughts

Your email address will not be published. Required fields are marked *